HIV Drug Resistance Assessment among Women who Seroconverted during the MTN-025/HOPE Open-Label Extension Dapivirine Vaginal Ring Trial.
Urvi M ParikhKerri J PenroseAmy L HeapsRahil SethiB Jay GoetzDaniel SzydloUma ChandranThesla Palanee-PhillipsNyaradzo M MgodiJared M BaetenJohn W Mellorsnull nullPublished in: Journal of acquired immune deficiency syndromes (1999) (2023)
NNRTI resistance among women who seroconverted during HOPE was infrequent and selection of dapivirine-specific mutations was not detected. Dapivirine ring is considered a safe and effective option for HIV prevention in women.
Keyphrases
- polycystic ovary syndrome
- open label
- pregnancy outcomes
- clinical trial
- phase iii
- phase ii
- study protocol
- breast cancer risk
- hiv infected
- antiretroviral therapy
- hiv positive
- hepatitis c virus
- type diabetes
- squamous cell carcinoma
- insulin resistance
- randomized controlled trial
- hiv aids
- hiv testing
- pregnant women
- metabolic syndrome
- men who have sex with men
- placebo controlled